English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

I read with interest the recent study by Sever et al. ,1 which reported that patients originally assigned atorvastatin continued to demonstrate lower event rates in most cardiovascular endpoints after the termination of Lipid Lowering Arm of the ASCOT (ASCOT-LLA) trial, compared with those originally assigned placebo, although LDL-cholesterol levels were almost identical in the two groups during the 2 years extended follow-up period.1 These observations suggest sustained cardioprotective effects of atorvastatin after the cessation of active treatment in at-risk patients with …

Possible involvement of advanced glycation end products in carry-over benefits of atorvastatin in ASCOT-BPLA